Search Results - "Bylicki, O"

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy by Bylicki, O., Gan, H.K., Joly, F., Maillet, D., You, B., Péron, J.

“…The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2013 to provide a set of specific recommendations regarding patient-reported…”
Get full text

Temporary endobronchial embolization with silicone spigots for moderate hemoptysis: a retrospective study by Bylicki, O, Vandemoortele, T, Laroumagne, S, Astoul, P, Dutau, H

“…The management of airway bleeding is generally performed in an emergency to prevent hypoxemia and lung flooding. When the bleeding arises from peripheral…”
Get more information

Symptoms of Long-COVID 1-Year after a COVID-19 outbreak among sailors on a French aircraft carrier by Perisse, A., De Cacqueray, F., Delarbre, D., Marsaa, H., Bergmann, C., Da Silva, V., Bronstein, A., Paleiron, N., Menoud, N., Cobola, J., Verret, C., Mayet, A., Bylicki, O.

“…•Prevalence of Long-COVID symptoms was 53.7%, 55.2% and 54.3% in COVID-positive patients at months 6, 9 and 12.•In COVID-negative patients, prevalence was…”
Get full text

Disseminated nocardiosis caused by Nocardia nova with brain abscesses and osteomyelitis in an immunocompetent patient by Conan, P-L, Ficko, C, Charton, F, Bylicki, O, Le Floch, H, Margery, J, Rivière, F

“…Nocardia is an opportunist bacteria involved in patients with cellular immunodepression or chronic lung disease. The most frequent portals of entry are the…”
Get full text

Tracheobronchomalacia in adults: breakthroughs and controversies by Dutau, H, Laroumagne, S, Bylicki, O, Vandemoortele, T, Astoul, P

“…Tracheobronchomalacia (TBM) in adults is a disease defined by a reduction of more than 50% of the airway lumen during expiration. It encompasses many…”
Get more information

Perforation of the nasal septum: a rare complication of bevacizumab by Bylicki, O, Boursier, C, Peloni, J-M, Dot, J-M

“…Neovascularisation is a hallmark of cancer. Vascular endothelial growth factor (VEGF) is directly involved in the regulation of this tumoural neoangiogenesis,…”
Get more information

Respiratory distress of unusual cause by de Charry, C, Bylicki, O, Mavrovi, E, Le Moigne, F, de Charry, F

Get full text

Late revelation of air embolism after transthoracic needle biopsy by Bylicki, O, Zarza, V, Marfisi-Dubost, A, Odier, L, Thomsom, V, Perol, M, Arpin, D

“…Percutaneous transthoracic needle biopsy is a useful and common procedure in the investigation of a lung nodule. The occurrence of air embolism after…”
Get full text

Evaluation of pneumococcal urinary antigen testing for respiratory tract infection investigations by Charton, F., Conan, P.L., Le Floch, H., Bylicki, O., Gaspard, W., Soler, C., Margery, J., Rivière, F.

“…•This study evaluated the use of pneumococcal urinary antigen testing for the diagnosis of lower respiratory tract infections, and identified factors…”
Get full text

1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019) by Descourt, R., Guisier, F., Pérol, M., Cadranel, J., Duruisseaux, M., Doubre, H., Culine, S., Lamour, C., Moro-Sibilot, D., Mennecier, B., Martin, N., Bylicki, O., Chouaid, C., Greillier, L.

Get full text

Embolie gazeuse de révélation tardive après ponction transpariétale pulmonaire by Bylicki, O., Zarza, V., Marfisi-Dubost, A., Odier, L., Thomsom, V., Perol, M., Arpin, D.

“…La ponction biopsie transpariétale est un geste de radiologie interventionnelle couramment effectué dans l’exploration d’un nodule pulmonaire. Ce geste est en…”
Get full text

1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy by Bronstein, A., Gervais, R., Monnet, I., Ricordel, C., Bigay-Game, L., Geier, M., Decroisette, C., Daniel, C., Guisier, F., Swalduz, A., Toffart, A.C., Doubre, H., Peloni, J.M., Arpin, D., Morel, H., Veillon, R., Clarisse, B., Chouaid, C., Greillier, L., Bylicki, O.

Get full text

1035P A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017) by Decroisette, C., Monnet, I., Ricordel, C., Demaegdt, A., Falchero, L., Bylicki, O., Geier, M., Justeaux, G., Bernardi, M., Andre, M., Guisier, F., Fournel, P., Vieillot, S., Hauss, P.A., Schott, R., Crequit, J., Auliac, J.B., Chouaid, C., Greillier, L.

Get full text

Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019) by Ricordel, C, Anota, A., Bernardi, M., Falchero, L, Auliac, J. B., Greillier, L, Bylicki, O., de Chabot, G., Demaegdt, A., Vergnenegre, A, Decroisette, C, Martel-Lafay, I., Chouaid, C, Guisier, F.

“…Consolidation immunotherapy (IO) has transformed the therapeutic landscape for patients (pts) with locally advanced NSCLC. Its impact on health-related quality…”
Get full text

A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017) by Decroisette, C, Monnet, I., Ricordel, C, Demaegdt, A., Falchero, L, Bylicki, O., Geier, M., Justeaux, G., Bernardi, M., Andre, M., Guisier, F., Fournel, P, Vieillot, S., Hauss, P.-A., Schott, R, Crequit, J., Auliac, J. B., Chouaid, C, Greillier, L

Get full text

962P Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019) by Ricordel, C., Anota, A., Bernardi, M., Falchero, L., Auliac, J.B., Greillier, L., Bylicki, O., De Chabot, G., Demaegdt, A., Vergnenegre, A., Decroisette, C., Martel-Lafay, I., Chouaid, C., Guisier, F.

Get full text

1154P Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer by Gendarme, S., Zebachi, S., Corre, R., Greillier, L., Justeau, G., Bylicki, O., Decroisette, C., Auliac, J.B., Guisier, F., Geier, M., Ricordel, C., Frelaut, M., Paillaud, E., Chouaid, C., Canouï-Poitrine, F.

Get full text

LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC) by Spicer, J.D., Gao, S., Liberman, M., Kato, T., Tsuboi, M., Lee, S-H., Chen, K-N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G., Bylicki, O., Garassino, M.C., Rodriguez Abreu, D., Chaft, J., Novello, S., Yang, J., Keller, S.M., Samkari, A., Wakelee, H.

Get full text

1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU) by Lena, H., Cadranel, J., Girard, N., Mazieres, J., Curcio, H., Gille, R., Madroszyk Flandin, A-C., Auliac, J.B., Bylicki, O., Rieux, C., Couraud, S., Barlesi, F., Pichon, E., Métivier, A-C., Almotlak, H., Pabst, L., Deldycke, C., Duchemann, B., De Gunten, L., Quantin, X.

Get full text

1411TiP GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies by Bylicki, O., Clarisse, B., Grellard, J-M., Swalduz, A., Castera-Tellier, M., Ferlandin, S., Monnet, I., Greillier, L., Descourt, R., Peron, J., Chouaid, C., Gervais, R.

Get full text